P.K. Morrow is the Head of the Oncology Therapeutic Area Unit (OTAU). In this role, PK is responsible for Takeda’s oncology R&D strategy and development portfolio.

Prior to joining Takeda, P.K. served as Chief Medical Officer at CRISPR Therapeutics, where she led a cross-functional team of physicians, scientists and support staff, overseeing end-to-end development of clinical programs spanning hematology, oncology, diabetes and cardiovascular disease states. She was responsible for the development of numerous drug candidates and for the implementation of strategic partnerships with academic institutions, key opinion leaders, regulatory agencies and biopharmaceutical collaborators to facilitate successful execution of clinical trials.

Before joining CRISPR, P.K. spent over a decade at Amgen, where she served as Vice President and Global Therapeutic Area Head of Hematology, GI Oncology, GU Oncology, and Bone Diseases. Before joining the industry, she held the role of Assistant Professor, Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center.